Contributor since: 2013
In Memory Of SA Contributor DoctoRx
Final Market Comments (Goodbye To Seeking Alpha)
Gilead: 'Failed' Remdesivir Solidarity Study Might Really Show Efficacy
Lowe's Looks Poised To Keep Going Higher
UPS: New CEO, New Strategy To Deliver Sustainable Alpha
Zoom: Total Available Market May Be Larger Than What Is Priced In
Tesla: How It Still May Deliver Sustainable Alpha
Nvidia: Why It's Still Early Innings
Long Zoom, Short NYC And LA
Novo Nordisk: Long-Term Growth By CV Risk Factor Reduction
Biotech's Q2:  Lots Of Candidates That May Deliver Alpha
Gilead: Perhaps A Value Trap No Longer
Why Gold May Be In For A Fall This Summer
How COVID Panic Can Be Leading To A New 'Goldilocks' Scenario
Tesla Says 'Catch Me If You Can' - But They Can't
Time To Look Beyond Today's Headlines
Second COVID Wave? Analysis And Updated Investment Strategy
Gold: Reasons To Stay Bullish On The Metal, And On Some Miners
Novo Nordisk: A Plan To Grow Into The 2030s
Regeneron: Growth Plans In Immuno-Oncology (ASCO Update)
AstraZeneca: Surprise At ASCO May Mean New Highs Ahead
NIH Study Supports Wide Use Of Gilead's Remdesivir In COVID-19
Gilead: Strategic Update - Focus On 'Defend/Extend' HIV Franchise
Regeneron: Cancer, COVID, And More Could Be Breaking Its Way
Gilead Reports (Part 1): Focus On Remdesivir For COVID-19
Why Gilead's COVID Drug May Be The Magic Bullet We Need
'Don't Fight The Fed' As The Wrong Strategy: A 2-3 Year Plan
Gold Is Good: Why I'm Adding In A Deflationary Meltdown
Why There's Less To This Oil Price Rally Than Meets The Eye
3 Antifragile Stocks I'm Buying, And Why I'm Starting Now
Three Little Words For Bonds: Still A Buy
Markets That Try Men's Souls: Of Techs And Technicals
Bouncing Biotechs: A Multi-Company Review
Utilities: Making The Case That Their Rally Has More Juice Left
Nvidia On The Way To Dominance In Tomorrow's AI-Centric World
Intuitive Surgical: High Growth Potential In Surgery, And Beyond
Merck Spins, And Falls:  Why I Am More Bullish Than The Street
Novo Nordisk's Insulin Products, Pipeline May Energize The Stock
O'Day Making Gilead Good, And Perhaps Great Again
Vertex Beats: How A High P/E Biotech May Be Undervalued